India · Delayed Price · Currency is INR Titan Biotech Statistics
Total Valuation
Titan Biotech has a market cap or net worth of INR 18.92 billion. The enterprise value is 18.94 billion.
| Market Cap | 18.92B |
| Enterprise Value | 18.94B |
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | Sep 22, 2026 |
Share Statistics
Titan Biotech has 51.65 million shares outstanding. The number of shares has decreased by -9.99% in one year.
| Current Share Class | 51.65M |
| Shares Outstanding | 51.65M |
| Shares Change (YoY) | -9.99% |
| Shares Change (QoQ) | -20.01% |
| Owned by Insiders (%) | 8.72% |
| Owned by Institutions (%) | n/a |
| Float | 16.42M |
Valuation Ratios
The trailing PE ratio is 44.08.
| PE Ratio | 44.08 |
| Forward PE | n/a |
| PS Ratio | 7.85 |
| PB Ratio | 9.33 |
| P/TBV Ratio | 9.33 |
| P/FCF Ratio | 90.50 |
| P/OCF Ratio | 58.68 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.90, with an EV/FCF ratio of 90.56.
| EV / Earnings | 48.98 |
| EV / Sales | 7.86 |
| EV / EBITDA | 36.90 |
| EV / EBIT | 41.09 |
| EV / FCF | 90.56 |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.05 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.28 |
| Interest Coverage | 65.71 |
Financial Efficiency
Return on equity (ROE) is 20.94% and return on invested capital (ROIC) is 16.23%.
| Return on Equity (ROE) | 20.94% |
| Return on Assets (ROA) | 11.89% |
| Return on Invested Capital (ROIC) | 16.23% |
| Return on Capital Employed (ROCE) | 20.33% |
| Weighted Average Cost of Capital (WACC) | 1.31% |
| Revenue Per Employee | 4.57M |
| Profits Per Employee | 733,630 |
| Employee Count | 527 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 2.13 |
Taxes
In the past 12 months, Titan Biotech has paid 134.93 million in taxes.
| Income Tax | 134.93M |
| Effective Tax Rate | 25.87% |
Stock Price Statistics
The stock price has increased by +135.49% in the last 52 weeks. The beta is -0.54, so Titan Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.54 |
| 52-Week Price Change | +135.49% |
| 50-Day Moving Average | 326.84 |
| 200-Day Moving Average | 311.27 |
| Relative Strength Index (RSI) | 64.41 |
| Average Volume (20 Days) | 42,937 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Titan Biotech had revenue of INR 2.41 billion and earned 386.62 million in profits. Earnings per share was 8.31.
| Revenue | 2.41B |
| Gross Profit | 1.25B |
| Operating Income | 426.33M |
| Pretax Income | 521.55M |
| Net Income | 386.62M |
| EBITDA | 473.09M |
| EBIT | 426.33M |
| Earnings Per Share (EPS) | 8.31 |
Balance Sheet
The company has 47.29 million in cash and 59.49 million in debt, with a net cash position of -12.20 million or -0.24 per share.
| Cash & Cash Equivalents | 47.29M |
| Total Debt | 59.49M |
| Net Cash | -12.20M |
| Net Cash Per Share | -0.24 |
| Equity (Book Value) | 2.03B |
| Book Value Per Share | 49.14 |
| Working Capital | 734.27M |
Cash Flow
In the last 12 months, operating cash flow was 322.48 million and capital expenditures -113.38 million, giving a free cash flow of 209.10 million.
| Operating Cash Flow | 322.48M |
| Capital Expenditures | -113.38M |
| Depreciation & Amortization | 46.76M |
| Net Borrowing | -47.70M |
| Free Cash Flow | 209.10M |
| FCF Per Share | 4.05 |
Margins
Gross margin is 51.72%, with operating and profit margins of 17.69% and 16.04%.
| Gross Margin | 51.72% |
| Operating Margin | 17.69% |
| Pretax Margin | 21.64% |
| Profit Margin | 16.04% |
| EBITDA Margin | 19.63% |
| EBIT Margin | 17.69% |
| FCF Margin | 8.68% |
Dividends & Yields
This stock pays an annual dividend of 0.40, which amounts to a dividend yield of 0.11%.
| Dividend Per Share | 0.40 |
| Dividend Yield | 0.11% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.34% |
| FCF Payout Ratio | 9.88% |
| Buyback Yield | 9.99% |
| Shareholder Yield | 10.09% |
| Earnings Yield | 2.27% |
| FCF Yield | 1.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on October 23, 2026. It was a forward split with a ratio of 1.25.
| Last Split Date | Oct 23, 2026 |
| Split Type | Forward |
| Split Ratio | 1.25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |